Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
WHO-EORTC classification for cutaneous lymphomas Willemze R; Jaffe ES; Burg G; Cerroni L; Berti E; Swerdlow SH; Ralfkiaer E; Chimenti S; Diaz-Perez JL; Duncan LM; Grange F; Harris NL; Kempf W; Kerl H; Kurrer M; Knobler R; Pimpinelli N; Sander C; Santucci M; Sterry W; Vermeer MH; Wechsler J; Whittaker S; Meijer CJBlood 2005[May]; 105 (10): 3768-85Primary cutaneous lymphomas are currently classified by the European Organization for Research and Treatment of Cancer (EORTC) classification or the World Health Organization (WHO) classification, but both systems have shortcomings. In particular, differences in the classification of cutaneous T-cell lymphomas other than mycosis fungoides, Sezary syndrome, and the group of primary cutaneous CD30+ lymphoproliferative disorders and the classification and terminology of different types of cutaneous B-cell lymphomas have resulted in considerable debate and confusion. During recent consensus meetings representatives of both systems reached agreement on a new classification, which is now called the WHO-EORTC classification. In this paper we describe the characteristic features of the different primary cutaneous lymphomas and other hematologic neoplasms frequently presenting in the skin, and discuss differences with the previous classification schemes. In addition, the relative frequency and survival data of 1905 patients with primary cutaneous lymphomas derived from Dutch and Austrian registries for primary cutaneous lymphomas are presented to illustrate the clinical significance of this new classification.|*World Health Organization[MESH]|Humans[MESH]|Immunophenotyping[MESH]|Lymphoma, T-Cell, Cutaneous/*classification/genetics/*pathology/therapy[MESH] |
